Part, Chapter, Paragraph
1 I, 2. 4 | inflate the growth rate. Table 2.1 provides an overview
2 I, 2. 4 | rapidly varying downward.~ ~Table 2.1. Growth rate of real
3 I, 2. 4 | observed (APPLICA, 2005; Table 2.2).~ ~Table 2.2. At risk
4 I, 2. 4 | APPLICA, 2005; Table 2.2).~ ~Table 2.2. At risk of poverty
5 I, 2. 6 | upper secondary education (Table 2.3) and of total early
6 I, 2. 6 | leavers (Figure 2.4).~ ~Table 2.3. Total population percentage
7 I, 2. 8 | generation below as shown in Table 2.4.~ ~ ~Table 2.4. Health
8 I, 2. 8 | shown in Table 2.4.~ ~ ~Table 2.4. Health impacts of different
9 II, 4. 1 | between different countries.~ ~Table 4.1.1 shows estimates for
10 II, 4. 1 | women, the gender gaps.~ ~Table 4.1.1. Life expectancy (
11 II, 4. 1 | and women, respectively (Table 4.1.1). Although in 2005
12 II, 4. 1 | an idea of likely trends. Table 4.1.2 gives estimates of
13 II, 4. 1 | with the ECHP survey.~ ~Table 4.1.2. Life expectancy and
14 II, 4. 1 | Robine and Michel, 2004).~ ~Table 4.1.3 shows 10-year trends
15 II, 4. 1 | the EU27 by gender. The table also displays the maximum,
16 II, 4. 1 | MS level within EU27.~ ~Table 4.1.3. Life expectancy at
17 II, 4. 1 | longevity gender gap by 1 year (Table 4.1.3). Estimates shown
18 II, 4. 1 | 1.3). Estimates shown in Table 4.1.3 for LE only suggest
19 II, 4. 1 | between the MS since 1995.~ ~Table 4.1.4. Minimum and maximum
20 II, 4. 1 | in 2005, per gender~ ~Table 4.1.4 underlines the significant
21 II, 4. 1 | 0 years gap) for women. Table 4.1.4 provides additional
22 II, 4. 1 | countries, LE does. Thus Table 4.1.7 presents the values
23 II, 4. 1 | and Welfare, 2006).5~ ~ ~Table 4.1.5. Life expectancy at
24 II, 4. 1 | 1995 and 2005, per gender~ ~Table 4.1.5 shows firstly that
25 II, 4. 1 | in Japan. Secondly, the table shows that gender gaps range
26 II, 4. 2 | the 1990s (2.7 years).~ ~Table 4.2.1 shows the contribution
27 II, 4. 2 | reaching even 40% for women.~ ~Table 4.2.1. Arriaga decomposition
28 II, 4. 2 | changes by causes of death. Table 4.2.2 shows the contribution
29 II, 4. 2 | one among men decreased.~ ~Table 4.2.2. Arriaga decomposition
30 II, 4. 2 | of death, EU15 average.~ ~Table 4.2.3 shows the Arriaga
31 II, 4. 2 | of the European Union.~ ~Table 4.2.3. Arriaga decomposition
32 II, 4. 2 | diseases (causes 6, 7 and 8 in table 3) has contributed most
33 II, 4. 2 | causes 2, 3, 4 and 5 in table 3), had a smaller impact
34 II, 4. 2 | gynaecological cancers (cause 4 in table 3) had a negative impact
35 II, 4. 2 | Infectious diseases (cause 1 in table 3) did not have a large
36 II, 4. 2 | respiratory diseases (cause 9 in table 3) declined in most countries.
37 II, 4. 2 | causes 10, 11 and 12 in table 3) has decreased in most
38 II, 4. 2 | related mortality (cause 13 in table 3) had a negative effect
39 II, 4. 2 | causes of death’ (cause 14 in table 3) across European countries.
40 II, 4. 2 | respiratory diseases.~ ~Table 4.2.4 shows by how many
41 II, 4. 2 | expectancy at birth. The table shows that for men in 7
42 II, 4. 2 | increase in life expectancy.~ ~Table 4.2.4. Contribution of change
43 II, 4. 2 | 2000, selected countries~ ~Table 4.2.5 shows that cancers
44 II, 4. 2 | larger than in the 1980s.~ ~Table 4.2.5. The effect of smoking
45 II, 4. 2 | 65+) in recent decades, table 6 shows the average change
46 II, 4. 2 | decades were selected.~ ~Table 4.2.6. Average annual change
47 II, 4. 2 | 65, selected countries.~ ~Table 4.2.6 shows that in 11 out
48 II, 4. 2 | larger than that for women.~ ~Table 4.2.7 shows the development
49 II, 4. 2 | between men and women.~ ~Table 4.2.7. Average annual change
50 II, 5. 1. 1 | non-communicable diseases (Table 5.1.1). On the other hand,
51 II, 5. 1. 1 | 2003), EU27 – B) Men.~ ~ ~ ~Table 5.1.1. Risk factors for
52 II, 5. 2. 3 | Eastern Europe countries (Table 5.2.1). According to the
53 II, 5. 2. 3 | France and 167 in Latvia).~ ~Table 5.2.1. Ischemic heart diseases (
54 II, 5. 2. 3 | 35-74 years~ ~Morbidity~ ~Table 5.2.2 shows IHD and AMI
55 II, 5. 2. 3 | trends in medical care.~ ~Table 5.2.2. Crude hospital discharge
56 II, 5. 2. 3 | considered and reported in Table 5.2.3 (Allender et al, 2008).
57 II, 5. 2. 3 | on patients with IHD.~ ~Table 5.2.3. Crude rates per 1
58 II, 5. 2. 3 | MONICA Project, reported in Table 5.2.4; here we can see mean
59 II, 5. 2. 3 | Working Group, 2003).~ ~Table 5.2.4. WHO-MONICA 13 EU
60 II, 5. 2. 3 | differences among countries.~ ~Table 5.2.5. Age-standardized (
61 II, 5. 2. 3 | times higher. As shown in table 5.2.5, in the age range
62 II, 5. 2. 3 | 35-84 years~ ~Morbidity~ ~Table 5.2.2 also shows stroke
63 II, 5. 2. 3 | These data are reported in Table 5.2.6: here mean attack
64 II, 5. 2. 3 | severity (Sarti et al, 2003).~ ~Table 5.2.6. WHO-MONICA Project
65 II, 5. 2. 4 | health examination surveys. Table 5.2.7 (htt b, 2007) provides
66 II, 5. 2. 4 | 140 o 90 mmHg; 160 mmHg).~Table 5.2.8 shows data on total
67 II, 5. 2. 4 | higher among elderly women.~Table 5.2.9 reports smoking habit
68 II, 5. 2. 4 | see also Chapter 8).~ ~Table 5.2.7. Estimated prevalence
69 II, 5. 2. 4 | ranges in 22 EU countries.~ ~Table 5.2.8. Estimated mean values
70 II, 5. 2. 4 | different age ranges.~ ~Table 5.2.9. Estimated prevalence
71 II, 5. 2. 4 | Obesity and overweight (Table 5.2.10) are also included
72 II, 5. 2. 4 | see also Chapter 10).~ ~Table 5.2.10. Estimated prevalence
73 II, 5. 2. 4 | the WHO-MONICA Project (Table 5.2.11) collected between
74 II, 5. 2. 4 | environmental conditions.~ ~Table 5.2.11. Prevalence of smoking (%),
75 II, 5. 3. 1 | public health relevance. Table 5.3.1 shows the burden of
76 II, 5. 3. 1 | as estimated in 2006.~ ~Table 5.3.1. Estimated incident
77 II, 5. 3. 7 | of EU Member States (see Table 5.3.2) consider national
78 II, 5. 3. 7 | improve cancer control.~ ~Table 5.3.2. Cancer national control
79 II, 5. 4. 2 | fundamental recommendations (Table 5.4.1). The Declaration
80 II, 5. 4. 2 | broader international level.~ ~Table 5.4.1. Recommendations St.
81 II, 5. 4. 2 | Greenfield et al 2004, see Table 5.4.2), only three were
82 II, 5. 4. 2 | and Outcomes Framework.~ ~Table 5.4.2. OECD indicators~ ~ ~
83 II, 5. 4. 2 | Tables 5.4.3 and 5.4.4.~ ~Table 5.4.3. EUDIP core indicators
84 II, 5. 4. 2 | as a secondary cause.~ ~Table 5.4.4. EUDIP secondary indicators
85 II, 5. 4. 6 | Luxembourg, 1-2 June 2006 (see Table 5.4.1);~ ~Table 5.4.1. EU
86 II, 5. 4. 6 | 2006 (see Table 5.4.1);~ ~Table 5.4.1. EU Council Recommendations~
87 II, 5. 4. 7 | include all aspects listed in table 5.4.5, which are highly
88 II, 5. 5. 1 | anxiety disorder was 14%. Table 5.5.1.1 presents lifetime
89 II, 5. 5. 1 | six ESEMeD countries.~ ~Table 5.5.1.1 Lifetime and 12
90 II, 5. 5. 1 | Practitioners (GP) only.~ ~Table 5.5.1.2. Level of care use (%)
91 II, 5. 5. 1 | generalised anxiety disorder.~ ~Table 5.5.1.3. Lifetime suicidal
92 II, 5. 5. 1 | and increased with age.~ ~Table 5.5.1.4. Psychological distress
93 II, 5. 5. 1 | psychological distress.~ ~Table 5.5.1.5. Odds Ratio for
94 II, 5. 5. 1 | Europe are presented in Table 5.5.1.6.~ ~Table 5.5.1.6.
95 II, 5. 5. 1 | presented in Table 5.5.1.6.~ ~Table 5.5.1.6. Annually age adjusted
96 II, 5. 5. 1 | approximately 12 years is given in Table 5.5.1.7.~ ~Table 5.5.1.7.
97 II, 5. 5. 1 | given in Table 5.5.1.7.~ ~Table 5.5.1.7. Age adjusted mortality
98 II, 5. 5. 1 | In the 0-14 age group (Table 5.5.1.8) the suicide rates
99 II, 5. 5. 1 | United Kingdom and Ireland.~ ~Table 5.5.1.8. Number of deaths (
100 II, 5. 5. 2 | suffering from dementia.~ ~Table 5.5.2.1. EURODEM prevalence
101 II, 5. 5. 2 | EURODEM prevalence rates~ ~Table 5.5.2.2. Prevalence rates
102 II, 5. 5. 2 | results are as follows:~ ~Table 5.5.2.3. The estimated number
103 II, 5. 5. 3 | countries. The overview in table 5.5.3.1.2.1 illustrates
104 II, 5. 5. 3 | participated in the project.~ ~Table 5.5.3.1.1 Overview of data
105 II, 5. 5. 3 | Sweden~ ~X~ ~Turkey~ ~X~ ~ ~Table 5.5.3.1.2.1: Available data
106 II, 5. 5. 3 | accounting for 6.2% YLDs).~Table 5.5.3.2.1. DALYs due to
107 II, 5. 5. 3 | important aspect of morbidity.~Table 5.5.3.2.2. Prevalence and
108 II, 5. 5. 3 | recommendations in guidelines (Table 5.5.3.2.3).~Table 5.5.3.
109 II, 5. 5. 3 | guidelines (Table 5.5.3.2.3).~Table 5.5.3.2.3. Psychosocial
110 II, 5. 5. 3 | Collaboration, 2003) – see table 5.5.3.2.4.~Table 5.5.3.2.
111 II, 5. 5. 3 | see table 5.5.3.2.4.~Table 5.5.3.2.4. European practice
112 II, 5. 5. 3 | and respective deficits.~Table 5.5.3.2.5. Mental health
113 II, 5. 5. 3 | for outpatient care (see Table 5.5.3.3.6). Since psychotic
114 II, 5. 5. 3 | Lindström et al, 2007)~Table 5.5.3.2.6. Expenditures
115 II, 5. 5. 3 | parts of the continent (Table 5.5.3.4.1). The annual incidence
116 II, 5. 5. 3 | children and in the elderly (Table 5.5.3.4.2), even with significant
117 II, 5. 5. 3 | and the study design.~ ~Table 5.5.3.4.1. Incidence of
118 II, 5. 5. 3 | of epilepsy in Europe~ ~Table 5.5.3.4.2. Incidence (per
119 II, 5. 5. 3 | from 3.2 to 7.8 per 1,000 (Table 5.5.3.4.3). The prevalence
120 II, 5. 5. 3 | incidence studies (see above).~ ~Table 5.5.3.4.3. Prevalence of
121 II, 5. 5. 3 | and adults (Jallon, 2004) (Table 5.5.3.4.4). These data are
122 II, 5. 5. 3 | symptomatic seizures.~ ~Table 5.5.3.4.4. Community-based
123 II, 5. 5. 3 | simple partial seizures)(Table 5.5.3.4.5). The issue of
124 II, 5. 5. 3 | patient-doctor relationship.~ ~Table 5.5.3.4.5. National legislations
125 II, 5. 5. 3 | Country, where available.~ ~Table 5.5.3.5.1. Prevalence of
126 II, 5. 5. 3 | selected EUGLOREH Countries~ ~Table 5.5.3.5.2. Prevalence (per
127 II, 5. 5. 3 | EUGLOREH Contries by gender~ ~Table 5.5.3.5.3. Prevalence (per
128 II, 5. 5. 3 | by age (best estimates)~ ~Table 5.5.3.5.4. Incidence (per
129 II, 5. 5. 3 | disease course is reported in Table 5.5.3.5.5 and Figure 5.5.
130 II, 5. 5. 3 | 35% (The Netherlands).~ ~Table 5.5.3.5.5. Proportion of
131 II, 5. 5. 3 | disability score is shown in Table 5.5.3.5.6 and Figure 5.5.
132 II, 5. 5. 3 | severe MS (EDSS 7-9.5)~ ~Table 5.5.3.5.6. Proportion of
133 II, 5. 5. 3 | in Europe is reported in Table 7 Decreasing trends over
134 II, 5. 5. 3 | range from about 30 to 45.~ ~Table 5.5.3.5.7. Mortality (per
135 II, 5. 5. 3 | different studies are shown in Table 5. 5. 3. 6. 1.~ ~Table 5.
136 II, 5. 5. 3 | in Table 5. 5. 3. 6. 1.~ ~Table 5.5.3.6.1. Incidence studies
137 II, 5. 5. 3 | prevalence are summarised in Table 5.5.3.6.2..(von Campenhausen
138 II, 5. 5. 3 | Campenhausen et al, 2005).~ ~Table 5.5.3.6.2. Prevalence studies
139 II, 5. 5. 3 | found in only a few studies (Table 5.5.3.6.3. Distribution
140 II, 5. 5. 3 | 1994; Mutch et al, 1986).~ ~Table 5.5.3.6.3. Distribution
141 II, 5. 6. 3 | Symmons, 2003) are given in table 5.6.1.~ ~Table 5.6.1. General
142 II, 5. 6. 3 | given in table 5.6.1.~ ~Table 5.6.1. General Incidence
143 II, 5. 6. 3 | intensive physical activity (Table 5.6.4). The pain and disability
144 II, 5. 6. 3 | Symmons et al, 2003).~ ~Table 5.6.2. Osteoarthritis Incidence
145 II, 5. 6. 3 | selected European countries~ ~Table 5.6.3. Osteoarthritis Prevalence
146 II, 5. 6. 3 | selected EUGLOREH Countries~ ~Table 5.6.4. Osteoarthritis Prevalence (
147 II, 5. 6. 3 | progression of radiographic OA (Table 5.6.4). Almost everyone
148 II, 5. 6. 3 | factors are summarised in table 5.6.5.~ ~Table 5.6.5. Risk
149 II, 5. 6. 3 | summarised in table 5.6.5.~ ~Table 5.6.5. Risk factors for
150 II, 5. 6. 3 | decline (Linos et al, 1980). (Table 5.6.6)~ ~Table 5.6.6. Prevalence
151 II, 5. 6. 3 | 1980). (Table 5.6.6)~ ~Table 5.6.6. Prevalence and incidence
152 II, 5. 6. 3 | or more is considerable (Table 5.6.7).~ ~Table 5.6.7. Estimated
153 II, 5. 6. 3 | considerable (Table 5.6.7).~ ~Table 5.6.7. Estimated lifetime
154 II, 5. 6. 3 | those more likely to fall (Table 5.6.8) and those who may
155 II, 5. 6. 3 | be at risk of fracture (Table 5.6.9). There are some semi-independent
156 II, 5. 6. 3 | spontaneously (Melton, 1995).~ ~Table 5.6.8. Risk Factors for
157 II, 5. 6. 3 | Falling in the Elderly~ ~Table 5.6.9. Risk factors for
158 II, 5. 6. 3 | years (Kanis et al, 2002) (Table 5.6.10).~ ~Table 5.6.10.
159 II, 5. 6. 3 | 2002) (Table 5.6.10).~ ~Table 5.6.10. Estimated 10 year
160 II, 5. 6. 4 | had rheumatoid arthritis (Table 5.6.11).~ ~Table 5.6.11.
161 II, 5. 6. 4 | arthritis (Table 5.6.11).~ ~Table 5.6.11. Distribution (in
162 II, 5. 6. 4 | the most common reason (Table 5.6.12). (European Commission (
163 II, 5. 6. 4 | Problems and Conditions)~ ~Table 5.6.12. Distribution (in
164 II, 5. 7. 1 | available GFR cut-offs.~ ~Table 5.7.1. KDIGO Definition
165 II, 5. 7. 1 | without kidney damage~ ~ ~ ~ ~Table 5.7.2. Current CKD Classification
166 II, 5. 7. 3 | was 7.1 patients pmarp (Table 5.7.3).~ ~Adults~ ~CKD incidence
167 II, 5. 7. 3 | patients pmp in Portugal (Table 5.7.4 and Table 5.7.5).
168 II, 5. 7. 3 | Portugal (Table 5.7.4 and Table 5.7.5). Just like prevalence,
169 II, 5. 7. 3 | in males than in females (Table 5.7.3). Whereas incidence
170 II, 5. 7. 3 | rate of diabetic ESRD.~ ~Table 5.7.3. Incidence of RRT
171 II, 5. 7. 3 | cause of renal failure.~ ~Table 5.7.4. Incidence of RRT
172 II, 5. 7. 3 | 2005 period per country~ ~Table 5.7.5. Incidence of RRT
173 II, 5. 7. 3 | increased by more than 50% (Table 5.7.3). This was primarily
174 II, 5. 7. 3 | disproportionally affected (Table 5.7.7), may depend on the
175 II, 5. 7. 3 | age related population (Table 5.7.7).~ ~Adults~ ~The prevalence
176 II, 5. 7. 3 | males compared to females (Table 5.7.7). Prevalence of RRT
177 II, 5. 7. 3 | System, USRDS ,2007).~ ~Table 5.7.6A. Prevalence of RRT
178 II, 5. 7. 3 | 1992-2005 by country.~ ~Table 5.7.6B. Prevalence of RRT
179 II, 5. 7. 3 | 2000-2005 by country.~ ~Table 5.7.7. Prevalence of RRT
180 II, 5. 7. 3 | over the period 1992-2005 (Table 5.7.7) the overall adjusted
181 II, 5. 7. 3 | years of age respectively (Table 5.7.8). Five-year mortality
182 II, 5. 7. 3 | progress (Young et al, 2000).~ ~Table 5.7.8. 90-day, one-, two-
183 II, 5. 7. 3 | disproportionally affected (Table 5.7.7), may depend on the
184 II, 5. 8. 2 | asthma (Viegi et al 2004).~ ~Table 5.8.2.1. ICD10 Codes for
185 II, 5. 8. 3 | more than four estimates (Table 5.8.1)~ ~Table 5.8.1. Prevalence
186 II, 5. 8. 3 | estimates (Table 5.8.1)~ ~Table 5.8.1. Prevalence estimates
187 II, 5. 8. 3 | disease, pulmonary embolism (Table 5.8.2).~ ~Table 5.8.2. Incidence
188 II, 5. 8. 3 | embolism (Table 5.8.2).~ ~Table 5.8.2. Incidence of comorbidities
189 II, 5. 9. 3 | East Germany, Australia).~ ~Table 5.9.1. Summary of data on
190 II, 5. 9. 3 | in prevalence of asthma~ ~Table 5.9.2. Summary of data on
191 II, 5. 9. 3 | in prevalence of asthma~ ~Table 5.9.3. Summary of studies
192 II, 5. 9. 4 | ragweed pollen counts.~ ~Table 5.9.4. Highest, median and
193 II, 5. 9. 4 | assessed by skin tests.~ ~Table 5.9.5. High or low prevalence
194 II, 5. 9. 4 | Parietaria; w1, ragweed.~ ~ ~Table 5.9.6. Standardized (age,
195 II, 5. 10. 2 | for a variety of purposes (Table 1). These include molecular
196 II, 5. 10. 2 | Brusic et al, 2003).~ ~Table 5.10.1. Available allergen
197 II, 5. 10. 2 | dermatitis due to ingested food (Table 2).~ ~Table 5.10.2. ICD
198 II, 5. 10. 2 | ingested food (Table 2).~ ~Table 5.10.2. ICD codes presumed
199 II, 5. 10. 5 | of the allergenic source (Table 5.10.1). Alcoholic beverages
200 II, 5. 10. 5 | reactions to foodstuffs.~ ~Table 5.10.3. List of food ingredients/
201 II, 5. 10. 5 | exempted form labelling (Table 5.10.1). It is to note that
202 II, 5. 11. 3 | Tables 5.11.1 and 5.11.2.~ ~Table 5.11.1. Prevalence of selected
203 II, 5. 11. 3 | Dermatol 2006;16:212-218~ ~ ~Table 5.11.2. Prevalence of examined
204 II, 5. 11. 3 | incidence, especially of NMSC (Table 5.11.3).~ ~Table 5.11.3.
205 II, 5. 11. 3 | of NMSC (Table 5.11.3).~ ~Table 5.11.3. Age-standardized
206 II, 5. 12. 3 | 5.12.2 (A and B).~ ~ ~ ~Table 5.12.1 gives the age-standardized
207 II, 5. 12. 3 | changes in percentage.~ ~Table 5.12.1. Age-adjusted (world
208 II, 5. 12. 3 | women from all countries (Table 5.12.2), but trends were
209 II, 5. 12. 3 | around 24-30/100,000).~ ~Table 5.12.2. Age-adjusted (world
210 II, 5. 12. 3 | European countries are given in Table 5.12.3 for men and in Table
211 II, 5. 12. 3 | Table 5.12.3 for men and in Table 5.12.4 for women. Given
212 II, 5. 12. 3 | in women from Ireland.~ ~Table 5.12.3. Joinpoint regression
213 II, 5. 12. 3 | EUGLOREH countries, 1970-2002~ ~Table 5.12.4. Joinpoint regression
214 II, 5. 14. 3 | decay severity (DMFT). (Table 5.14.1). For instance, the
215 II, 5. 14. 3 | Denmark is 1.0 DMF-T.~ ~Table 5.14.1. Dental Health in
216 II, 6. 3. 1 | diseases under surveillance (Table 6.1). Of the 49 diseases,
217 II, 6. 3. 1 | influenza, AMR and malaria).~ ~Table 6.1. Summary of general
218 II, 6. 3. 4 | Tuberculosis Annual Report~ ~ ~ ~ ~Table 6.A1.1 Number of cases of
219 II, 6. 3. 4 | cases (Sweden smear)~ ~ ~Table 6.A1.2 Cases of TB between
220 II, 6. 3. 4 | between 1995 and 2004~ ~ ~ ~Table 6.A1.3 Cases of TB by age
221 II, 7. 3. 1 | Injuries~ ~The figures given in Table 7.1 are based on a data
222 II, 7. 3. 1 | view of injuries (CVI) in Table 7.1. Comprehensive view
223 II, 7. 3. 1 | for injury surveillance.~ ~Table 7.1. Comprehensive view
224 II, 7. 3. 2 | comprehensive view of injuries in Table 7.1, fatal injuries are
225 II, 7. 3. 2 | system claim more lives (Table 7.2. Leading cause of death
226 II, 7. 3. 2 | per age group, EU27).~ ~Table 7.2. Leading cause of death
227 II, 7. 3. 3 | inpatients treated for injuries (Table 7.3).~ ~Table 7.3. Hospital
228 II, 7. 3. 3 | injuries (Table 7.3).~ ~Table 7.3. Hospital discharge
229 II, 7. 3. 5 | medically treated cases (See Table 7.1).~ ~Suicide and self
230 II, 7. 4. 1 | all young people’s deaths (Table 7.2. Leading cause of death
231 II, 7. 4. 5 | leisure and sports” domain (Table 7.1) and that in most home,
232 II, 8. 1. 3 | and women aged 16-64.~ ~Table 8.1. Proportion of people
233 II, 8. 2. 2 | and Candidate Countries (Table 8.2) due to different assumptions
234 II, 8. 2. 2 | in Murray et al, 2001).~ ~Table 8.2. Prevalence of blindness
235 II, 8. 2. 2 | cataract in EUR-B countries (Table 8.3). Glaucoma and diabetic
236 II, 8. 2. 2 | in developed countries.~ ~Table 8.3. Causes of blindness
237 II, 8. 2. 2 | and Candidate Countries (Table 8.2) due to different assumptions
238 II, 8. 2. 2 | in Murray et al, 2001).~ ~Table 8.2. Prevalence of blindness
239 II, 8. 2. 2 | cataract in EUR-B countries (Table 8.3). Glaucoma and diabetic
240 II, 8. 2. 2 | in developed countries.~ ~Table 8.3. Causes of blindness
241 II, 8. 2. 3 | performance are presented in Table 8.4. Available data have
242 II, 8. 2. 3 | H90-H91) (WHO, 2002).~ ~Table 8.4. WHO grades of hearing
243 II, 8. 2. 3 | results obtained are shown in Table 8.5. An additional study
244 II, 8. 2. 3 | estimated to be 0.1 to 0.2%.~ ~Table 8.5. Estimated prevalence
245 II, 9 | Tables from 9.1.a to 9.1.d.~ ~Table 9.1a. Main risk factors
246 II, 9 | listed in Chapter 9.1.1~ ~ ~ ~Table 9.1b. Main risk factors
247 II, 9 | References cited in this table are listed in Chapter 9.
248 II, 9 | listed in Chapter 9.2~ ~ ~Table 9.1c. Main risk factors
249 II, 9 | References cited in this table are listed in Chapter 9.
250 II, 9 | listed in Chapter 9.3.1~ ~ ~Table 9.1d. Main risk factors
251 II, 9 | References cited in this table are listed in Chapter 9.
252 II, 9. 1. 1 | among EU Member States. Table 9.1.1.1 provides definitions
253 II, 9. 1. 1 | countries and over time.~ ~Table 9.1.1.1. Definitions of
254 II, 9. 1. 1 | as neonatal mortality~ ~Table 9.1.1.2. Births, deaths
255 II, 9. 1. 1 | EURO-PERISTAT indicators, listed in Table 1, were developed after
256 II, 9. 1. 1 | in the member states.~ ~Table 9.1.1.2.1. EURO-PERISTAT
257 II, 9. 1. 1 | Reproduction and Embryology). Table 9. 1. 1. 2. 1 indicates
258 II, 9. 1. 1 | neonatal and infant mortality~ ~Table 9.1.1.2 provides rates of
259 II, 9. 1. 1 | mortality, as explained in Table 9.1.1.1. In addition, data
260 II, 9. 1. 1 | the first year of life.~ ~Table 9.1.1.3. Infant mortality
261 II, 9. 1. 1 | live births. As shown in Table 9.1.1.4, this rate varies
262 II, 9. 1. 1 | 2.3 (United Kingdom).~ ~Table 9.1.1.4. Cerebral palsy
263 II, 9. 1. 1 | impairment. As shown in Table 9.1.1.5, these proportions
264 II, 9. 1. 1 | time in this rate of CP.~ ~Table 9.1.1.5. Proportion of severe
265 II, 9. 1. 1 | period 1990-1998. As shown in Table 9.1.1.6, this rate varies
266 II, 9. 1. 1 | 1499g (Platt et al, 2007).~ ~Table 9.1.1.6. CP rates among
267 II, 9. 1. 1 | available knowledge see Table 9.1 and the section on maternal
268 II, 9. 1. 2 | registers in 20 countries (see Table 9.1.2.2.1), covering in
269 II, 9. 1. 2 | participate in EUROCAT (Table 1), as well as the Ukraine
270 II, 9. 1. 2 | full membership in 2009.~ ~Table 9.1.2.2.1. Coverage of the
271 II, 9. 1. 2 | each country is shown in Table 1, ranging among those countries
272 II, 9. 1. 2 | 000 births for 2000-2004 (Table 9.1.2.1). Total prevalence
273 II, 9. 1. 2 | 19.9 per 1 000 births.~ ~Table 9.1.2.1. Prevalence per
274 II, 9. 1. 2 | subgroups in Europe is shown in Table 9.1.2.1. The prevalence
275 II, 9. 1. 2 | births. In the data shown in Table 9.1.2.1, these cases have
276 II, 9. 1. 2 | 000 births are shown in Table 9.1.2.1.~ ~There has been
277 II, 9. 1. 2 | of 0.99 per 1 000 births (Table 9.1.2.2). The main congenital
278 II, 9. 1. 2 | chromosomal anomalies (21%) (Table 9.1.2.2).~ ~Chromosomal
279 II, 9. 1. 2 | equally in both categories.~ ~Table 9.1.2.2. Perinatal mortality
280 II, 9. 1. 2 | anomaly varies per country (Table 9.1.2.3). The lowest rates
281 II, 9. 1. 2 | mortality statistics).~ ~Table 9.1.2.3. Ratio of Terminations
282 II, 9. 1. 2 | Norway, Portugal, Denmark).~ ~Table 9.1.2.3 shows TOPFA before
283 II, 9. 1. 2 | with congenital anomaly (Table 9.1.2.3). Up to 0.8% (Switzerland)
284 II, 9. 1. 2 | record a rate above 0.5% (Table 9.1.2.3). The differences
285 II, 9. 1. 2 | is 6.1 per 1 000 births (Table 9.1.2.1), the largest group
286 II, 9. 1. 2 | in Ireland and Malta).~ ~Table 9.1.2.4. Total and live
287 II, 9. 1. 2 | 1.0 per 1 000 in Poland (Table 9.1.2.4).~ ~Orofacial clefts~ ~
288 II, 9. 1. 2 | 1 000 births in Europe (Table 9.1.2.1). Cleft lip with
289 II, 9. 1. 2 | 000 births in 2000-2004 (Table 9.1.2.1). It is associated
290 II, 9. 1. 2 | of 1.3 per 1 000 births (Table 9.1.2.1). Individual registries
291 II, 9. 1. 2 | For main risk factors see Table 9.1a.~ ~Table 9.1a. Main
292 II, 9. 1. 2 | factors see Table 9.1a.~ ~Table 9.1a. Main risk factors
293 II, 9. 1. 2 | prevention have been presented in Table 9.1a. The following would
294 II, 9. 2. 2 | indicators are published as Table 6 of the report as far as
295 II, 9. 2. 4 | for children health (see Table 9.1b.). Equally important -
296 II, 9. 2. 4 | policies and legislation.~ ~ ~Table 9.1b. Main risk factors
297 II, 9. 2. 4 | References cited in this table are listed in Chapter 9.
298 II, 9. 3. 1 | and injury and poisoning (Table 9.3.1.1). For men who survive
299 II, 9. 3. 1 | smaller than at birth.~ ~Table 9.3.1.1 Premature mortality
300 II, 9. 3. 1 | adults are summarized in Table 9.1c.~ ~Table 9.1c. Main
301 II, 9. 3. 1 | summarized in Table 9.1c.~ ~Table 9.1c. Main risk factors
302 II, 9. 3. 1 | References cited in this table are listed in Chapter 9.
303 II, 9. 3. 2 | available knowledge see Table 9.1a.~ ~The EURO-PERISTAT
304 II, 9. 3. 2 | women of reproductive age (Table 9.1a) using data from EUROSTAT,
305 II, 9. 3. 2 | between EU Member States.~ ~Table 9.3.2.1. Percentage of babies
306 II, 9. 4. 2 | supporting this theory.~ ~Table 9.4.1. General Physical
307 II, 9. 4. 3 | for falls are listed in Table 4.1. These difficulties
308 II, 9. 4. 3 | estimates for 1996).~ ~Table 9.4.2. Most common causes
309 II, 9. 4. 4 | elderly are summarized in Table 9.1d.~ ~Table 9.1d. Main
310 II, 9. 4. 4 | summarized in Table 9.1d.~ ~Table 9.1d. Main risk factors
311 II, 9. 4. 4 | References cited in this table are listed in Chapter 9.
312 II, 9. 5. 3 | isolation (Doyal, 1998).~ ~Table 9.5.1. Sex differences in
313 II, 9. 5. 3 | greater longevity of women~ ~ ~Table 9.5.2. Prevalence of depression
314 II, 9. 5. 3 | epidemiological studies~ ~Table 9.5.3. Suicide Rates~ ~Gender
315 II, 9. 5. 3 | similar (Eurostat, 2006).~ ~Table 9.5.4. Percentage of 25-
316 II, 9. 5. 3 | sources, are reported in Table 9.5.5.~ ~Table 9.5.5. Violence
317 II, 9. 5. 3 | reported in Table 9.5.5.~ ~Table 9.5.5. Violence against
318 II, 9. 5. 3 | respectively (Jernigan, 2001).~ ~Table 9.5.6 below illustrates
319 II, 9. 5. 3 | in the UK and Ireland.~ ~Table 9.5.6. Drinking patterns
320 II, 9. 5. 3 | related health problems.~ ~Table 9.5.7. Percentage of Female
321 II, 9. 5. 3 | physical activity at work.~ ~Table 9.5.8. Days of vigorous
322 II, 9. 5. 3 | last 7 days per gender~ ~Table 9.5.9. Time spent on vigorous
323 II, 9. 5. 4 | Control tools and policies~ ~Table 9.5.10. European Parliament
324 III, 10. 1 | 10.1.2 and, together with Table 10.1.1, by Figure 10.1.3.~ ~ ~ ~
325 III, 10. 1 | determinants and human beings~ ~ ~Table 10.1.1. Health determinants:
326 III, 10. 1 | the case of cancer/EMF.~ ~Table 10.1.2. Major health impacts
327 III, 10. 2. 1 | leading causes of death.~ ~Table 10.2.1.1.1. Diseases caused
328 III, 10. 2. 1 | asterisk, suggestive~ ~ ~Table 10.2.1.1.2. Diseases and
329 III, 10. 2. 1 | smoking is presented in Table 10.2.1.1.3., for the main
330 III, 10. 2. 1 | diseases for the year 2000.~ ~Table 10.2.1.1.3. Deaths from
331 III, 10. 2. 1 | described by the World Bank.~ ~Table 10.2.1.1.4. Selected EUGLOREH
332 III, 10. 2. 1 | during the previous 12 months Table 10.2.1.2.1. The proportion
333 III, 10. 2. 1 | at least once a week.~ ~Table 10.2.1.2.1. Frequency of
334 III, 10. 2. 1 | adversely affected by alcohol.~ ~Table 10.2.1.2.2. Change in death
335 III, 10. 2. 1 | consumption~ ~As can be seen in Table 10.2.1.2.2, there are significant
336 III, 10. 2. 1 | surveys have been presented in Table 10.2.3.1.~ ~Table 10.2.1.
337 III, 10. 2. 1 | presented in Table 10.2.3.1.~ ~Table 10.2.1.3.1. Conservative
338 III, 10. 2. 1 | related to the use of drugs (Table 10.2.1.3.2).~ ~Table 10.
339 III, 10. 2. 1 | drugs (Table 10.2.1.3.2).~ ~Table 10.2.1.3.2 – Problem Drug
340 III, 10. 2. 1(15)| See Table DRD-2 (i), Table DRD-3 and
341 III, 10. 2. 1(15)| See Table DRD-2 (i), Table DRD-3 and Table DRD-4 in
342 III, 10. 2. 1(15)| DRD-2 (i), Table DRD-3 and Table DRD-4 in the 2007 statistical
343 III, 10. 2. 1 | Gherunpong et al, 2006)~ ~Table 10.2.1.5.1 illustrates the
344 III, 10. 2. 1 | Honkala and Rimpelä, 2007).~ ~Table 10.2.1.5.1. Children Daily
345 III, 10. 2. 1 | affects most adolescents (Table 10.2.5.1) and 40 to 50%
346 III, 10. 2. 1 | Managers is reported in Table 10.2.1.7.0.~ ~Table 10.2.
347 III, 10. 2. 1 | reported in Table 10.2.1.7.0.~ ~Table 10.2.1.7.0 Preliminary information
348 III, 10. 2. 1 | food items is reported in table 10.2.1.7.1 whereas the gross
349 III, 10. 2. 1 | in EU15, 2002 (1 000 t)~ ~Table 10.2.1.7.1. Gross human
350 III, 10. 2. 1 | cereals, 2004 (1 000 t)~ ~Table 10.2.1.7.2. Gross human
351 III, 10. 2. 1 | consumption of meat, 2003~ ~Table 10.2.1.7.3. Gross human
352 III, 10. 2. 1 | fruits, 2004 (1 000 t)~ ~Table 10.2.1.7.4. Gross human
353 III, 10. 2. 1 | surveys are reported in Table 10.2.1.7.5.~ ~Table 10.2.
354 III, 10. 2. 1 | reported in Table 10.2.1.7.5.~ ~Table 10.2.1.7.5. DAFNE average
355 III, 10. 2. 1 | compared to WHO/FAO goals (table 10.2.1.7.7), there is little
356 III, 10. 2. 1 | and wholemeal products.~ ~Table 10.2.1.7.6. Comparisons
357 III, 10. 3. 1 | of physical risk factors (table 10.3.1.1). Physical work
358 III, 10. 3. 1 | or moving heavy loads.~ ~Table 10.3.1.1. Self-reported
359 III, 10. 3. 2 | of all exports in 2004.~ ~Table 10.3.2.1. Some industrial
360 III, 10. 3. 2 | industrial applications.~ ~Table 10.3.2.2. Platinum group
361 III, 10. 3. 2 | Rhine and tributaries~ ~Table 10.3.2.2 shows levels of
362 III, 10. 3. 2 | including flame retardants.~ ~Table 10.3.2.3 below overviews
363 III, 10. 3. 2 | very difficult to assess.~ ~Table 10.3.2.3 . Major health
364 III, 10. 3. 2 | much of the information in Table 10.3.2.3. is based on observations
365 III, 10. 3. 3 | segments and risk groups) (table 10.3.3.1).~ ~Table 10.3.
366 III, 10. 3. 3 | groups) (table 10.3.3.1).~ ~Table 10.3.3.1. Summary of general
367 III, 10. 3. 4 | the impacts these have (Table 10.3.4.1). Finally, it highlights
368 III, 10. 3. 4 | control and policy tools.~ ~Table 10.3.4.1. Global trends
369 III, 10. 3. 4 | Extreme weather events~ ~Table 10.3.4.2 gives an overview
370 III, 10. 3. 4 | affected most people.~ ~Table 10.3.4.2. Deaths and damage
371 III, 10. 4. 1 | values and limit values (Table 10.4.1.1).~ ~Table 10.4.
372 III, 10. 4. 1 | values (Table 10.4.1.1).~ ~Table 10.4.1.1. Guidelines, target
373 III, 10. 4. 1 | serious health impacts. Table 10.4.1.2 here below describes
374 III, 10. 4. 1 | current legislation in 2020.~ ~Table 10.4.1.2. Estimated health
375 III, 10. 4. 1 | et al and re-analyses~ ~Table 10.4.1.3. The CAFE analysis
376 III, 10. 4. 2 | food chain "from farm to table";~· greater integration
377 III, 10. 4. 2 | can be present in food (Table 10.4.2.1), in particular
378 III, 10. 4. 2 | associated with zoonoses (Table 10.4.2.2). In humans, the
379 III, 10. 4. 2 | threatening conditions (Table 10.4.2.3 The infection can
380 III, 10. 4. 2 | risks to public health.~ ~Table 10.4.2.1. Association of
381 III, 10. 4. 2 | Hepatitis E virus~ ~ ~Pig~ ~ ~ ~Table 10.4.2.2. Zoonotic diseases
382 III, 10. 4. 2 | Wildilife~Source: EFSA~ ~ ~Table 10.4.2.3. Disease symptoms
383 III, 10. 4. 2 | prevalence was apparent in table eggs over the last 5 years.~·
384 III, 10. 4. 2 | as contaminants in feed (Table 10.4.2.4). With respect
385 III, 10. 4. 2 | European countries.~ ~ ~Table 10.4.2.4. Not naturally
386 III, 10. 4. 2 | impact on consumer’s health (Table 10.4.2.5).~ ~Nitrates~ ~
387 III, 10. 4. 2 | cooking (EFSA, 2007b).~ ~ ~Table 10.4.2.5. Naturally occurring,
388 III, 10. 4. 2 | food chain, from farm to table.~ ~EFSA is also proactive
389 III, 10. 4. 2 | for exports into the EU.~ ~Table 10.4.2.6. FVO Inspection
390 III, 10. 4. 2 | European Member States.~ ~Table 10.4.2.7. Food safety competent
391 III, 10. 4. 5 | groundwater in Europe~ ~Table 10.4.5.2.1. Overview of
392 III, 10. 4. 5 | chlorinated hydrocarbons (CHC) (Table 10.4.5.2.1). Mineral oil
393 III, 10. 5. 2 | Reilly et al., 2007).~ ~Table 10.5.2.1. Variations in
394 III, 10. 5. 2 | by urbanization levels:~ ~Table 10.5.2.2. Percentage and
395 III, 10. 5. 2 | less-developed EU countries.~ ~ ~Table 10.5.2.3. Problems accessing
396 III, 10. 5. 3 | least once in 12 months (Table 10.5.3.1). This results
397 III, 10. 5. 3 | health & social work.~ ~Table 10.5.3.1. Absence from work
398 III, 10. 5. 3 | additionally to 1900 fatal events (table 10.5.3.2). The incidence
399 III, 10. 5. 3 | carpal tunnel syndrome (Table 10.5.3.3).~Economic sectors
400 III, 10. 5. 3 | by occupational diseases (table 10.5.3.4). A top incidence
401 III, 10. 5. 3 | of app. 60 per 100,000.~ ~Table 10.5.3.2. Number and incident
402 III, 10. 5. 3 | occupational diseases.~ ~Table 10.5.3.3. Number of non
403 III, 10. 5. 3 | occupational diseases by ICD10.~ ~Table 10.5.3.4. Number and incident
404 III, 10. 5. 3 | work (serious accidents) (Table 10.5.3.5) and accidents
405 III, 10. 5. 3 | accidents see also Chapter 7.~ ~Table 10.5.3.5. Incidence of work
406 III, 10. 5. 3 | peak in the year 2000.~ ~Table 10.5.3.6 gives time trends
407 III, 10. 5. 3 | across economic sectors. Table 10.5.3.7 points to especially
408 III, 10. 5. 3 | accidents at work increased.~ ~Table 10.5.3.6. Change in the
409 III, 10. 5. 3 | employment from 1994 to 2004~ ~Table 10.5.3.7. Standardised incidence
410 III, 10. 5. 3 | risk because of their work (table 10.5.3.8). This perceived
411 III, 10. 5. 3 | fatigue, stress and headache (table 10.5.3.9). There seems to
412 III, 10. 5. 3 | difference between sexes. Table 10.5.3.10 finally gives
413 III, 10. 5. 3 | impact of their work.~ ~Table 10.5.3.8. Perceived impact
414 III, 10. 5. 3 | on health per country~ ~Table 10.5.3.9. Perceived impact
415 III, 10. 5. 3 | on health per symptoms.~ ~Table 10.5.3.10. Perceived work-related
416 III, 10. 5. 3 | so with men than women (table 10.5.3.11). About 40% of
417 III, 10. 5. 3 | monotonous or repetitive tasks.~ ~Table 10.5.3.11. Work organisational
418 III, 10. 5. 3 | manufacturing and agriculture (table 10.5.3.12). A lack of job
419 III, 10. 5. 3 | transport and communication.~ ~Table 10.5.3.12. Work organisational
420 III, 10. 5. 3 | of physical risk factors (table 10.5.3.13). Exposures to
421 III, 10. 5. 3 | to the economic sectors (table 10.5.3.14). Especially employees
422 III, 10. 5. 3 | all the working time.~ ~Table 10.5.3.13. Physical risks
423 III, 10. 5. 3 | factors at work per gender.~ ~Table 10.5.3.14. Physical risks
424 III, 10. 6. 1 | social support categories.~ ~Table 10.6.1. Social support by
425 III, 10. 6. 2 | lower educational groups (Table 10.6.2.1).~ ~Table 10.6.
426 III, 10. 6. 2 | groups (Table 10.6.2.1).~ ~Table 10.6.2.1. Odds Ratio Chronic
427 IV, 11. 1. 3 | 500 per capita in 2004 (table 11.1). Luxembourg spends
428 IV, 11. 1. 3 | per capita at US$4,603.~ ~Table 11.1. Private and Public
429 IV, 11. 1. 5 | part of the variation.~ ~Table 11.2. Perceived quality
430 IV, 11. 1. 6 | these negative incentives. Table 11.3 shows the physician
431 IV, 11. 1. 6 | physicians in Europe.~ ~Table 11.3. Physician payment
432 IV, 11. 1. 6 | as a form of payment (see Table 11.3). While DRGs are a
433 IV, 11. 2. 1 | al, 2004), and below.~ ~Table 11.4. Number of outpatient
434 IV, 11. 2. 1 | decline in most countries (Table 11.5). The exceptions are
435 IV, 11. 2. 1 | increase was seen.~ ~F ~ ~Table 11.5. Number of psychiatric
436 IV, 11. 3. 1 | and financial reasons.~ ~Table 11.6. Numbers of practising
437 IV, 11. 3. 2 | system. Indeed, as shown in Table 11.7, the growth in spending
438 IV, 11. 3. 2 | in the Czech Republic (Table 11.7).~ ~Additionally, while
439 IV, 11. 3. 2 | and Turkey (HFA 2007).~ ~Table 11.7. Spending on pharmaceuticals
440 IV, 11. 3. 2 | or company agreements.~ ~Table 11.8. Contribution of European
441 IV, 11. 6. 1 | and Mossialos, 1999).~ ~Table 11.9. Total health care
442 IV, 11. 6. 1 | percentage of GDP, 1990-2004~ ~Table 11.10. Total health care
443 IV, 11. 6. 2 | degree of public expenditure. Table 11.11 shows that the public
444 IV, 11. 6. 2 | OECD Health data 2006).~ ~Table 11.11. Public expenditure
445 IV, 11. 6. 2 | and Latvia). As shown in Table 11.12, the countries with
446 IV, 11. 6. 2 | private insurance funds.~ ~Table 11.12. Financing mix separated
447 IV, 11. 6. 2 | individuals and are summarized in Table 11.13. Also in some countries,
448 IV, 11. 6. 2 | Foubister and Mossialos 2008).~ ~Table 11.13. Examples for cost
449 IV, 11. 6. 4 | health insurance funds (Table 11.14), the resources generated
450 IV, 11. 6. 4 | van de Ven et al 2007).~ ~Table 11.14. Collection and allocation
451 IV, 12. 1 | initiatives in the field (Table 12.1). Even today, public
452 IV, 12. 1 | Member State competence.~ ~Table 12.1. Health – related precursor
453 IV, 12. 1 | health” (Article 152(1)) (Table 12.2). Whilst the Amsterdam
454 IV, 12. 1 | health is not surprising (Table 12.2).~ ~Table 12.2. EU
455 IV, 12. 1 | surprising (Table 12.2).~ ~Table 12.2. EU Treaty Articles
456 IV, 12. 1 | half a billion citizens (Table 12.3). Prevention has the
457 IV, 12. 1 | and public expectations.~ ~Table 12.3. Some examples highlighting
458 IV, 12. 1 | provisions of the Treaty (see Table 12.3), related to the movement
459 IV, 12. 2 | Tables 12.4 and 12.5.~ ~Table 12.4. Policies and control
460 IV, 12. 2 | starting in 2007. ~ ~ ~ ~Table 12.5. Policies and control
461 IV, 12. 4 | directorates other than D.G. SANCO (Table 12.6).~ ~Table 12.6. Health
462 IV, 12. 4 | D.G. SANCO (Table 12.6).~ ~Table 12.6. Health across the
463 IV, 12. 4 | for health policy makers (Table 12.7). Working as technical
464 IV, 12. 4 | was established in 2006.~Table 12.7. Community agencies
465 IV, 12. 4 | for health is provided in Table 12.8.~ ~ ~Table 12.8. Financial
466 IV, 12. 4 | provided in Table 12.8.~ ~ ~Table 12.8. Financial community
467 IV, 12. 5 | built on multiple lines (Table 12.9).~ ~Table 12.9. Actions
468 IV, 12. 5 | multiple lines (Table 12.9).~ ~Table 12.9. Actions referred to
469 IV, 12. 8 | 15 to 27 member States (Table 12.10) started in the health
470 IV, 12. 8 | country in December 2005.~ ~ ~Table 12.10. The 27 European Union
471 IV, 13. 1 | for mortality data see Table 13.3). Large differences
472 IV, 13. 1 | different EU countries.~ ~Table 13.1. Standardised Death
473 IV, 13. 2. 2 | health loss.~ ~A summary table of the results of the global
474 IV, 13. 2. 2 | population, EU25, EU15 (Table 13.4).~ ~Table 13.2. Global
475 IV, 13. 2. 2 | EU25, EU15 (Table 13.4).~ ~Table 13.2. Global burden of disease
476 IV, 13. 2. 2 | specific diseases are shown in Table 13.5.~ ~ ~Table 13.3. Additional
477 IV, 13. 2. 2 | shown in Table 13.5.~ ~ ~Table 13.3. Additional estimations
478 IV, 13. 2. 3 | world range from 2-6%.~ ~Table 13.4. Burden of disease
479 IV, 13. 2. 3 | first three determinants in Table 13.6 are typically associated
480 IV, 13. 2. 3 | 49 selected conditions. Table 13.7 presents a comparison
481 IV, 13. 2. 3 | diseases and depression. Table 13.7 also shows that the
482 IV, 13. 2. 3 | in different people.~ ~ ~Table 13.5. Annual health loss (
483 IV, 13. 2. 3 | lifestyle factors’ in this table~4. It is assumed here that
484 IV, 13. 2. 4 | Disease in European countries (Table 13.8).~ ~ ~Table 13.6. WHO
485 IV, 13. 2. 4 | countries (Table 13.8).~ ~ ~Table 13.6. WHO estimates for
486 IV, 13. 2. 4 | factors in the European Union (Table 13.6) are smoking, having
487 IV, 13. 2. 4 | from the data reported in Table 13.6 that these risk factors
